Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
Copyright © 2023 Elsevier Inc. All rights reserved..
Wu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
---|---|
Enthalten in: |
Cancer cell - 41(2023), 5 vom: 08. Mai, Seite 821-823 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wu, Mary Y [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 11.05.2023 Date Revised 20.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.ccell.2023.04.005 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM356200485 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM356200485 | ||
003 | DE-627 | ||
005 | 20240320233112.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ccell.2023.04.005 |2 doi | |
028 | 5 | 2 | |a pubmed24n1337.xml |
035 | |a (DE-627)NLM356200485 | ||
035 | |a (NLM)37116490 | ||
035 | |a (PII)S1535-6108(23)00131-9 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Wu, Mary Y |e verfasserin |4 aut | |
245 | 1 | 0 | |a Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 11.05.2023 | ||
500 | |a Date Revised 20.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
520 | |a Wu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants | ||
650 | 4 | |a Letter | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a sotrovimab |2 NLM | |
650 | 7 | |a 1MTK0BPN8V |2 NLM | |
700 | 1 | |a Shepherd, Scott T C |e verfasserin |4 aut | |
700 | 1 | |a Fendler, Annika |e verfasserin |4 aut | |
700 | 1 | |a Carr, Edward J |e verfasserin |4 aut | |
700 | 1 | |a Au, Lewis |e verfasserin |4 aut | |
700 | 1 | |a Harvey, Ruth |e verfasserin |4 aut | |
700 | 1 | |a Dowgier, Giulia |e verfasserin |4 aut | |
700 | 1 | |a Hobbs, Agnieszka |e verfasserin |4 aut | |
700 | 1 | |a Herman, Lou S |e verfasserin |4 aut | |
700 | 1 | |a Ragno, Martina |e verfasserin |4 aut | |
700 | 1 | |a Adams, Lorin |e verfasserin |4 aut | |
700 | 1 | |a Schmitt, Andreas M |e verfasserin |4 aut | |
700 | 1 | |a Tippu, Zayd |e verfasserin |4 aut | |
700 | 1 | |a Shum, Benjamin |e verfasserin |4 aut | |
700 | 1 | |a Farag, Sheima |e verfasserin |4 aut | |
700 | 1 | |a Rogiers, Aljosja |e verfasserin |4 aut | |
700 | 1 | |a O'Reilly, Nicola |e verfasserin |4 aut | |
700 | 1 | |a Bawumia, Philip |e verfasserin |4 aut | |
700 | 1 | |a Smith, Callie |e verfasserin |4 aut | |
700 | 1 | |a Carlyle, Eleanor |e verfasserin |4 aut | |
700 | 1 | |a Edmonds, Kim |e verfasserin |4 aut | |
700 | 1 | |a Del Rosario, Lyra |e verfasserin |4 aut | |
700 | 1 | |a Lingard, Karla |e verfasserin |4 aut | |
700 | 1 | |a Mangwende, Mary |e verfasserin |4 aut | |
700 | 1 | |a Holt, Lucy |e verfasserin |4 aut | |
700 | 1 | |a Ahmod, Hamid |e verfasserin |4 aut | |
700 | 1 | |a Korteweg, Justine |e verfasserin |4 aut | |
700 | 1 | |a Foley, Tara |e verfasserin |4 aut | |
700 | 1 | |a Barber, Taja |e verfasserin |4 aut | |
700 | 1 | |a Hepworth, Stephanie |e verfasserin |4 aut | |
700 | 1 | |a Emslie-Henry, Andrea |e verfasserin |4 aut | |
700 | 1 | |a Caulfield-Lynch, Niamh |e verfasserin |4 aut | |
700 | 1 | |a Byrne, Fiona |e verfasserin |4 aut | |
700 | 1 | |a Deng, Daqi |e verfasserin |4 aut | |
700 | 1 | |a Williams, Bryan |e verfasserin |4 aut | |
700 | 1 | |a Brown, Michael |e verfasserin |4 aut | |
700 | 1 | |a Caidan, Simon |e verfasserin |4 aut | |
700 | 1 | |a Gavrielides, Mike |e verfasserin |4 aut | |
700 | 1 | |a MacRae, James I |e verfasserin |4 aut | |
700 | 1 | |a Kelly, Gavin |e verfasserin |4 aut | |
700 | 1 | |a Peat, Kema |e verfasserin |4 aut | |
700 | 1 | |a Kelly, Denise |e verfasserin |4 aut | |
700 | 1 | |a Murra, Aida |e verfasserin |4 aut | |
700 | 1 | |a Kelly, Kayleigh |e verfasserin |4 aut | |
700 | 1 | |a O'Flaherty, Molly |e verfasserin |4 aut | |
700 | 1 | |a Popat, Sanjay |e verfasserin |4 aut | |
700 | 1 | |a Yousaf, Nadia |e verfasserin |4 aut | |
700 | 1 | |a Jhanji, Shaman |e verfasserin |4 aut | |
700 | 1 | |a Tatham, Kate |e verfasserin |4 aut | |
700 | 1 | |a Cunningham, David |e verfasserin |4 aut | |
700 | 1 | |a Van As, Nicholas |e verfasserin |4 aut | |
700 | 1 | |a Young, Kate |e verfasserin |4 aut | |
700 | 1 | |a Furness, Andrew J S |e verfasserin |4 aut | |
700 | 1 | |a Pickering, Lisa |e verfasserin |4 aut | |
700 | 1 | |a Beale, Rupert |e verfasserin |4 aut | |
700 | 1 | |a Swanton, Charles |e verfasserin |4 aut | |
700 | 1 | |a Gandhi, Sonia |e verfasserin |4 aut | |
700 | 1 | |a Gamblin, Steve |e verfasserin |4 aut | |
700 | 1 | |a Bauer, David L V |e verfasserin |4 aut | |
700 | 1 | |a Kassiotis, George |e verfasserin |4 aut | |
700 | 1 | |a Howell, Michael |e verfasserin |4 aut | |
700 | 1 | |a Walker, Susanna |e verfasserin |4 aut | |
700 | 1 | |a Nicholson, Emma |e verfasserin |4 aut | |
700 | 1 | |a Larkin, James |e verfasserin |4 aut | |
700 | 1 | |a Wall, Emma C |e verfasserin |4 aut | |
700 | 1 | |a Turajlic, Samra |e verfasserin |4 aut | |
700 | 0 | |a CAPTURE consortium |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancer cell |d 2002 |g 41(2023), 5 vom: 08. Mai, Seite 821-823 |w (DE-627)NLM119589826 |x 1878-3686 |7 nnns |
773 | 1 | 8 | |g volume:41 |g year:2023 |g number:5 |g day:08 |g month:05 |g pages:821-823 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ccell.2023.04.005 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 41 |j 2023 |e 5 |b 08 |c 05 |h 821-823 |